A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma
This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin ’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population where therapeutic options are limited due to poor tolerance.
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018
Publication date: Available online 25 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avi Leader, Noam Benyamini, Anat Gafter-Gvili, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Sabina De Geest, Pia RaananiAbstractBackgroundNonadherence to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has been associated with inferior outcomes. Scarce evidence exists on the effectiveness of adherence-enhancing interventions. The present pilot study evaluated the feasibility and effectiveness of an interventi...
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS, a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].
Publication date: Available online 17 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Wasithep Limvorapitak, Michael Barnett, Donna Hogge, Donna Forrest, Thomas Nevill, Sujaatha Narayanan, Maryse Power, Stephen Nantel, Raewyn Broady, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, Alina Gerrie, Jennifer White, David SanfordAbstract (245 word of 250 words recommended)IntroductionOptimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia (AML) remains an area of ongoing research. We aimed to retrospectively compare outcomes following autoSCT with allogeneic SCT (allo...
ConclusionSince WT1 expression correlated to known prognostic factors, the prognostic impact of WT1 levels might be misunderstood depending on the distribution of collaborative mutations in each cohort. We conclude that the prognostic significance of WT1 at diagnosis of AML is weak compared to other established prognostic factors.
Plasma cell myeloma (PCM) is a clonal plasma cell neoplasm characterized by high morbidity and mortality. Recent advances in therapy starting in the mid-1990s have improved the outcome but the 5-year survival rate is only 50.2% [1 –3], indicating the need for continued development of novel therapies. Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) has achieved dramatic results in multiply relapsed and/or treatment resistant B-cell lymphoma and acute B-lymphoblastic leukemia [4,5] making it an attractive therap eutic approach for PCM.
Conditions: Multiple Myeloma; Acute Leukemia; Chronic Leukemia; Lymphoma; Myelodysplastic Syndromes Interventions: Drug: Nivolumab; Drug: Tocilizumab Sponsor: Medical College of Wisconsin Not yet recruiting
The association between Wilms tumor 1 (WT1) expression, genetic abnormalities and homozygous single polymorphism (SNP) in WT1 gene was evaluated in 252 acute myelogenous leukemia (AML) patients. WT1 expression correlated with prognostic genetic abnormalities. Homozygous WT1 SNP rs16754 was associated with lower expression of WT1. WT1 expression had no prognostic impact in any cytogenetic group or SNP status.
We compared outcomes for patients with acute myeloid leukemia (AML) with intermediate risk karyotype receiving consolidation with: autologous stem cell transplant (autoSCT), matched sibling and unrelated allogeneic SCT (alloSCT) or chemotherapy. Consolidation with sibling alloSCT provided the best outcome. The long-term outcomes of autoSCT were comparable to unrelated alloSCT.
To the editor,